PAT as a Catalyst for Digital Transformation: Lessons for Engineers and Pharma Professionals at the 2025 ISPE Pharma 4.0™ Conference
For the first time in ISPE Pharma 4.0™ Conference history, ISPE will dedicate an entire track for the 2025 ISPE Pharma 4.0™ Conference to Process Analytical Technology (PAT)—in recognition of how central it has become to digital transformation in pharmaceutical manufacturing. The promise of PAT goes far beyond data collection of data analyzation. Its real value lies in enabling better decision-making, supporting continuous processes, improving supply chain resilience, and designing and embedding quality directly into manufacturing process and supporting systems.
This track will showcase how PAT is evolving from a set of technical tools into a cornerstone of digital transformation strategy. Presenters from Bayer, NNE, Recipharm, Novalix, Bruker, Pfizer, and others will demonstrate how PAT is being applied in real-world manufacturing environments—from plug-and-produce architectures to requirement settings for PAT integration into the control system to mRNA manufacturing and continuous active pharmaceutical ingredient (API) production. Importantly, attendees will also learn how PAT is being leveraged to address systemic vulnerabilities that were exposed as a result of the COVID-19 pandemic.
“As the track chair, I am very excited to see how PAT is being reborn as a strategic driver and enabler for digital transformation,” shared Line Lundsberg-Nielsen, PhD, Managing Consultant for NNE.
Why PAT Matters Now
For years, PAT was often considered a powerful technology for gaining process understanding during process development and a niche technology for manufacturing with limited examples on implementation for routine production and process control. That perspective has changed. With Pharma 4.0™ and digital transformation sweeping across our industry, PAT is no longer optional; it’s a strategic necessity.
- It allows for real-time monitoring and control, essential in continuous processes where intermediates are not isolated.
- It supports data-driven decision-making, reducing reliance on offline sampling and subjective interpretation.
- It enables predictive and adaptive control and can even be enhanced with AI, digital twins, and smart manufacturing platforms.
- It strengthens the supply chain, offering flexible, modular manufacturing solutions that can adapt to demand or disruption.
This track highlights practical case studies where PAT has delivered measurable improvements in quality, cost, and time-to-market.
Session Highlights
“Building the Foundation for Plug-and-Play PAT in Manufacturing”
This session takes a critical look at how PAT implementation often starts without a clear roadmap, requiring teams to define functional requirements from scratch. Attendees will see how operational needs—not just technology—drive design decisions. The second half of the presentation addresses a challenge many engineers face: the complexity of integrating diverse PAT equipment into existing IT/OT infrastructures.
Why it matters for engineers and pharma professionals: Industry professionals are all too familiar with integration headaches—equipment that doesn’t communicate, proprietary systems that resist interoperability, or interfaces that require endless customization. This session’s vision of standardized, flexible plug-and-produce functionality is vital for enabling PAT to scale.
“Smart mRNA Manufacturing Using PAT and Digitalization”
mRNA manufacturing is resource-intensive and costly, with expensive raw materials and high stakes for failure. This case study shows how a Raman-based PAT system was developed to monitor critical IVT process components—nucleotide triphosphates (NTPs), capping reagents, and mRNA concentrations—in real time. By partnering with the US Food and Drug Administration (US FDA) and the Massachusetts Institute of Technology (MIT), the team built a knowledge library and trained machine learning models to enable predictive, adaptive control.
The results? Real time quality control, faster manufacturing times, and integration with a digital twin platform that further reduced development cycles to under one month.
Why it matters for engineers and pharma professionals: This is a model example of how PAT, combined with AI and digital twins, moves beyond monitoring into automated process control. For those interested in mRNA technology, speeding up new product development, this is a session not to miss.
“PIPAC Project: Intelligent Production of API”
The COVID-19 pandemic exposed just how fragile global pharmaceutical supply chains can be. The Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) project aims to address this with compact, mobile, and autonomous API manufacturing units. These units apply Industry 4.0 principles—automation, modularity, connectivity, and AI-driven adaptability—to create a new paradigm for local pharmaceutical production.
PAT is at the heart of this approach, enabling continuous flow synthesis, as infrared and nuclear magnetic resonance spectroscopy provide continuous monitoring, and AI dynamically adjusts parameters in response to process changes.
Why it matters for engineers and pharma professionals: Imagine a future where API production can be scaled or relocated rapidly, reducing dependency on centralized plants or strained logistics. This project demonstrates how PAT is not just a quality enabler, but also a strategic tool for resilience and equity in global medicine access.
Implementation of PAT in Continuous API Manufacturing
Pfizer’s Flexible API Supply Technology (FAST) platform reimagines API manufacturing through modular, “plug-and-produce” unit operations. PAT is integral to this vision, enabling real-time monitoring and control in processes where intermediates are not isolated and dynamics change rapidly.
This session will walk through the design, validation, qualification, and implementation of PAT systems within the FAST framework, illustrating how Pfizer integrated hardware, software, and distributed control systems to achieve a state of control.
Why it matters for engineers and pharma professionals: Continuous API manufacturing is becoming increasingly important, and PAT is the linchpin that makes it viable. Attendees will leave this session with practical insights into designing PAT systems that not only validate and control processes but also deepen process understanding.
What Attendees Will Take Away
From this track, pharmaceutical manufacturing engineers can expect to leave with:
- Integration strategies: How to implement PAT systems that connect seamlessly across IT/OT infrastructures
- Cost and efficiency focus: Practical ways PAT reduces waste, accelerates release, and optimizes resource use
- Continuous manufacturing insights: Real-world examples of how PAT enables control strategies in continuous API production
- Supply chain resilience models: How modular, AI-driven PAT systems could transform global API availability
- Forward-looking vision: A sense of where PAT is heading in Pharma 4.0, including plug-and-produce, AI integration, and digital twin applications
Why the Authors Are Excited About This Track
As program committee members and track leaders, the authors see this track as a turning point. For too long, PAT has been misrepresented as just being a specialized tool. At the 2025 ISPE Pharma 4.0™ Conference, PAT takes its rightful place as a strategic enabler of digital transformation.
This track will not only broaden our understanding of what PAT can do today, but also inspire industry professionals to think about how to design future facilities, processes, and supply chains with PAT as a core pillar.
The PAT as an Enabler for Digital Transformation track brings together practical case studies, bold innovations, and a clear vision for the future of pharma manufacturing. For engineers and pharma professionals, it’s a chance to see how PAT can solve the problems we face daily—while also positioning our organizations for the long-term shifts in technology, regulation, and patient demand.
Don’t miss the chance to learn, question, and engage with PAT experts during this first true dedicated PAT Pharma 4.0 track and the closing panel discussion. This is not just another technical track; it’s a blueprint for how we can transform our plants, our supply chains, and our profession.
